Zealand Pharma A/S Q1 2025 Earnings Report

Zealand Pharma A/S EPS Results

• Actual EPS: -$0.67
• Consensus EPS: -$0.77
• Beat/Miss: Beat by +$0.10
• One Year Ago EPS: N/A

Zealand Pharma A/S Revenue Results

• Actual Revenue: $1.14 million
• Expected Revenue: $248.61 million
• Beat/Miss: Missed by -$247.47 million
• YoY Revenue Growth: N/A

Zealand Pharma A/S Announcement Details

• Quarter: Q1 2025
• Date: 5/8/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Zealand Pharma A/S (OTCMKTS:ZLDPF) is a biotechnology company headquartered in Denmark that discovers, develops and commercializes peptide-based medicines. Its research focuses primarily on metabolic and gastrointestinal diseases, including obesity, diabetes and rare disorders. The company develops therapies designed to address significant unmet medical needs through its expertise in peptide chemistry and drug delivery.

Zealand’s marketed product portfolio includes Zegalogue (dasiglucagon), an emergency treatment for severe hypoglycemia in people with diabetes. The company has also developed several investigational medicines, including petrelintide, an amylin analog being studied for weight management, and other peptide-based candidates for metabolic and gastrointestinal conditions. Zealand previously discovered lixisenatide, which was developed and commercialized through a collaboration with Sanofi under the names Adlyxin and Lyxumia.

Founded in 1998, Zealand Pharma serves international markets through its own activities and collaborations with pharmaceutical partners. Its development programs have included partnerships with companies such as Boehringer Ingelheim, particularly in obesity and related metabolic diseases. Zealand is led by President and Chief Executive Officer Adam Steensberg and is headquartered in Søborg, Denmark.